Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhy combining these two medicines is not a clinical option, and how to think about switching instead
The misconception: 'doubling up' would speed things up
The idea that taking two GLP-1 class medicines at once might accelerate weight loss is understandable. Both Wegovy (semaglutide) and Mounjaro (tirzepatide) reduce appetite, slow gastric emptying and are associated with meaningful weight loss in large clinical trials. If one is effective, the logic goes, two might be better.
That logic does not hold clinically. Wegovy is a GLP-1 receptor agonist. Mounjaro is a dual GIP and GLP-1 receptor agonist — the same GLP-1 pathway is already activated by both. Stacking them does not open a new route; it floods the same system. The main result is a substantially higher burden of gastrointestinal side effects: persistent nausea, vomiting and diarrhoea that risks dehydration and, in serious cases, can affect kidney function. There is also no published evidence that dual use produces superior weight loss. The detailed clinical answer to mixing Mounjaro and Wegovy sets out the risk picture in full.
Neither medicine is licensed for concurrent use with the other. A UK prescriber following MHRA guidance and their professional obligations cannot prescribe them together. The question our prescribers hear most weeks is not whether to combine them, but which one to use and whether it makes sense to switch, which is an entirely different, and reasonable, clinical question.
Switching from one to the other: what the clinical picture actually looks like
Switching between Wegovy and Mounjaro does happen. Patients transfer between them for several reasons: availability, tolerability, a plateau in weight loss, or a clinical reassessment suggesting one mechanism may suit their profile better. This is not the same as taking them together.
A switch requires a careful washout and retitration plan. Because both medicines slow gastric emptying and suppress appetite, overlapping doses even briefly during a transition can produce the same additive side-effect burden described above. The prescriber needs to know your current dose, how long you have been on it, and your weight at the point of transfer. Evidence of where you are in treatment matters, nume does not approve dose increases or switches without that picture being clear.
The clinical comparison matters here too. SURMOUNT-5, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4mg in adults with obesity and found greater average weight reduction with tirzepatide over 72 weeks. That does not automatically make Mounjaro the right choice for every person: tolerability, medical history, other medicines and lifestyle all factor in. The guide to switching from Mounjaro to Wegovy covers what a prescriber considers before agreeing to a transfer.
Wegovy and Mounjaro side by side: the facts that matter when choosing
Both medicines are licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Both are prescription-only, require clinical assessment, and are Black Triangle medicines subject to additional MHRA monitoring. The mechanisms and trial profiles differ, which is why a comparison is worth having before any prescription decision.
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Dosing range (UK) | 2.5mg–15mg once weekly (injection) | 0.25mg–2.4mg once weekly (injection); up to 7.2mg with newer pen |
| Average weight loss in trials | ~20–21% at 15mg over 72 weeks (SURMOUNT-1, NEJM) | ~15% at 2.4mg over 68 weeks (STEP 1, NEJM) |
| Head-to-head evidence | Tirzepatide showed greater average loss vs semaglutide 2.4mg in SURMOUNT-5 (NEJM, 2025) | |
| UK licence for weight management | Yes (NICE TA1026) | Yes (NICE TA875) |
The cost comparison between the two medicines is worth reading separately, prices shifted considerably after Eli Lilly's list-price change in September 2025. For the broader treatment picture, the head-to-head breakdown covers tolerability, eligibility and mechanism in depth.
One practical point: Ozempic is also semaglutide, but it is licensed for type 2 diabetes, not weight loss, and should not be conflated with Wegovy. The NHS tirzepatide page and the NHS semaglutide page both give clear patient-level information on their respective medicines.
How to choose between Wegovy and Mounjaro, and what comes next
The clinical answer is not "whichever shows the bigger trial number", it is the one that fits your health profile, your current medicines, your tolerability and your circumstances. Tirzepatide's dual mechanism is associated with larger average trial results, but some people do very well on semaglutide and some find its side-effect profile easier to manage early on. There is no universal answer.
What a prescriber needs to know includes your BMI, any relevant conditions, what medicines you currently take, whether you have tried a GLP-1 class medicine before, and your expectations. That is what the consultation is for. The clinical note on mixing semaglutide and tirzepatide reinforces why one replaces the other, never joins it.
Which medicine suits you is a clinical decision our prescribers make with you, not something a comparison table resolves on its own. Speak to our prescribers through a free consultation, reviewed the same day, with same-day dispatch once approved.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.